Share

    


In This Section

Home / Advocate / Letters and Statements

Letters and Statements

ACCC writes and signs on to letters to Congress and the Administration to promote our policy interests. We also write advocacy statements, blog posts, and opinion pieces on a wide range of topics in cancer care. Questions related to health policy? Contact Christian Downs, JD, MHA, President, CMI Association Management.

Follow ACCC (@ACCCBuzz) on Twitter for late-breaking cancer policy news and announcements.

Latest Letters

  • ACCC Writes Letter to the House Committee of Ways and Means in Support of H.R. 2407
    June 28, 2024

    ACCC joined over 500 organizations nationwide writing in support of the bipartisan Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407). ACCC members are all too familiar with the toll cancer takes on patients when diagnosed at a late stage. Early detection and treatment are crucial for improving cancer outcomes and saving lives.

    ACCC is very happy to learn that the legislation passed unanimously out of the House Ways and Means Committee on June 27, 2024.
    Read the Letter

  • ACCC Submits Letters to CMS on PFS and OPPS Regulations
    September 15, 2023

    On September 11, 2023, ACCC submitted comment letters to the Centers for Medicare and Medicaid Services (CMS) on the proposed physician fee schedule (PFS) and hospital outpatient prospective payment system (OPPS) regulations. Among other topics, ACCC supported the proposal for Medicare reimbursement for principal illness navigation (PIN) services to assist those with serious illnesses such as cancer.
    Read the First Letter Read the Second Letter

  • ACCC Signs Letter in Support of the Reducing Hereditary Cancer Act
    March 21, 2023

    ACCC joins a broad coalition of patients, advocacy organizations, cancer centers, and healthcare professionals to express support for the Reducing Hereditary Cancer Act. This crucial piece of legislation would address unacceptable care gaps in Medicare beneficiary access to genetic testing for hereditary cancer risk, evidence-based screening, and risk-reducing interventions, when medically necessary and appropriate.
    Read the Letter

  • ACCC Asks Congress to Improve Access to Genetic Counselors in End-of-Year Package
    November 28, 2022

    ACCC joined more than 250 organizations in asking congressional leadership to include the Access to Genetic Counselor Services Act (S. 1450/H.R. 2144) in an end-of-year legislative package. This piece of legislation would allow the Medicare program to directly reimburse genetic counselors, improving Medicare beneficiary access to comprehensive genetic counseling services.
    Read the Letter

  • ACCC Joins Radiation Oncology Community in Letter to Congress
    November 21, 2022

    In a letter to congressional leadership, ACCC joined the American Society for Radiation Oncology (ASTRO) and more than 20 other organizations asking Congress to pass legislation before the end of the year to prevent significant Medicare payment cuts to radiation therapy services. These cuts largely stem from the 2023 Medicare Physician Fee Schedule, PAYGO sequester, and clinical labor price updates.
    Read the Letter

Recent Advocacy News Releases

  • ACCC Applauds Senate Leaders for Introducing Bipartisan Legislation to Expand Medicare Coverage of Early Cancer Screenings

    Jun 30, 2023

    Senators Mike Crapo, Michael Bennet, Tim Scott, and Ben Cardin introduced the Medicare Multi-Cancer Early Detection Screening Coverage Act (S. 2085) last week. This important legislation provides Medicare with the authority to cover the latest innovative cancer screening technologies once they have been approved by the Food and Drug Administration. With these MCED tests, clinicians will be able to screen for dozens of types of cancers at once --- many of which currently have no early detection methods.

  • ACCC Statement on Chemotherapy Drug Shortages

    Jun 14, 2023

    The Association of Community Cancer Centers (ACCC) is highly concerned about the ongoing shortages of platinum-based chemotherapy agents (e.g., cisplatin and carboplatin), two medications that (individually or in combination) treat and cure a wide range of cancers, including but not limited to gastric, pancreatic, colorectal, esophageal, cervical, and ovarian.

  • ACCC Thankful for Inclusion of Key Priorities in Omnibus Package

    Dec 21, 2022

    The Association of Community Cancer Centers (ACCC) is grateful that Congress is poised to address many of our year-end policy priorities in its proposed fiscal year 2023 omnibus appropriations package released this week.

  • ACCC Statement on the Supreme Court Decision in Dobbs v. Jackson Women’s Health

    Jul 14, 2022

    In the wake of the Supreme Court’s recent decision on Dobbs overturning its 1973 ruling on Roe v. Wade, the Association of Community Cancer Centers (ACCC) has become increasingly concerned with the impact this decision may have on patients with cancer and their care teams.